Almirall, S.A. (0O9B.L)
| Previous close | 10.34 |
| Open | 10.30 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 10.30 - 10.30 |
| 52-week range | 8.11 - 11.29 |
| Volume | |
| Avg. volume | 48,403 |
| Market cap | 1.807B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Almirall’s H1 2024 Results: Almirall Delivers Strong Performance in the First Half of 2024, Achieving Net Sales Growth of 6.7% Driven by Its European Dermatology Business and Accelerating Biologics Sales
BARCELONA, Spain, July 22, 2024--Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its financial results from the first half of 2024. Almirall continued to deliver strong sales growth in the second quarter of 2024 which was mainly driven by the dermatology business in Europe. Total Net Sales increased by 6.7% to a total of €497.2 MM, EBITDA was €104.5 MM (increase of 3.2% YoY) driven by higher sales growth, with a gross margin of 65,1%. Dermatology sales
- GlobeNewswire
Eloxx Pharmaceuticals Provides Pipeline and Financing Updates
First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations Positive written FDA feedback and guidance from a pre-Investigational New Drug Application (PIND) meeting provides pathway to IND application submission to initiate a Phase 2 clinical trial in the US with ELX-02 in patients with nonsense mutation alport syndrome (NMAS) Secured binding commitment for addi
- Business Wire
NICE Recommends Ebglyss (lebrikizumab) for Use in Moderate to Severe Atopic Dermatitis in the NHS England in Eligible Adolescents and Adults
UXBRIDGE, England, July 10, 2024--Almirall S.A. (BME: ALM), a global biopharmaceutical company dedicated to medical dermatology, announced today that the National Institute for Health and Care Excellence (NICE) has recommended Ebglyss (lebrikizumab) for use in moderate to severe Atopic Dermatitis in the NHS England.
